Molecular Targeting Technologies, Inc. And National Health Research Institutes Have Joined Forces In Developing Novel Cancer Therapeutics
8/5/2014 10:21:44 AM
WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) and National Health Research Institutes (NHRI), Taiwan announced today that the two parties have formed a joint collaboration in developing novel cancer therapeutics, using the proprietary DPA delivery technology to carry anticancer drugs that can be specifically delivered to and released at the tumor sites. This collaboration has recently successfully achieved proof-of-concept in preclinical xenograft models and is now moving toward the next major milestone, which is the selection of a candidate for clinical development.
Help employers find you! Check out all the jobs and post your resume.
comments powered by